Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Blood Tests to Measure Ovarian Reserves in Women with a BRCA Mutation or Women Treated for Early-Stage Breast Cancer
Glossary on
off
Printer Friendly Page Blood Tests to Measure Ovarian Reserves in Women with a BRCA Mutation or Women Treated for Early-Stage Breast Cancer

Blood Tests to Measure Ovarian Reserves in Women with a BRCA Mutation or Women Treated for Early-Stage Breast Cancer

Clinicaltrials.gov identifier:
NCT00823654

Prevention
Study for premenopausal women with early-stage breast cancer and high-risk women with BRCA mutations and no evidence of breast or ovarian cancer

Study Contact Information:

For additional information, please contact:

Shari Goldfarb, MD at: 646-888-5080

Kimberly Van Zee, MD at: 646-888-5362


Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations

About the Study

The purpose of this study is to see how cancer treatment affects the ovaries, such as the impact on conceiving a child or the early onset of menopause. Comparatively, the study will also look at high-risk women with BRCA1/2 mutations (and no evidence of breast or ovarian cancer).

The study will check blood levels of hormones that the ovaries produce and will use questionnaires to gather information about participant menstrual cycles, health, and pregnancies. 

What the Study Entails

The study will enroll two groups of participants:

  • Premenopausal women with breast cancer
  • High-risk women with mutations (and no evidence of breast or ovarian cancer)

Patients in both of the study groups will undergo blood draws, complete questionnaires, and provide monthly menstrual calendars to the study team at intervals for approximately two years.   

For the high-risk women with mutations (and no evidence of breast or ovarian cancer), they have an option to participate in annual follow-up for an additional three years.

New Jersey

City: Basking Ridge RECRUITING
Facility: Memorial Sloan Kettering Basking Ridge
Contact Info:
646-888-5080

City: Middletown RECRUITING
Facility: Memorial Sloan Kettering Monmouth
Contact Info:
646-888-5080

City: Montvale RECRUITING
Facility: Memorial Sloan Kettering Bergen
Contact Info:
646-888-5080

New York

City: Commack RECRUITING
Facility: Memorial Sloan Kettering Commack
Contact Info:
646-888-5080

City: Harrison RECRUITING
Facility: Memorial Sloan Kettering Westchester
Contact Info:
646-888-5080

City: New York RECRUITING
Facility: Memorial Sloan Kettering Cancer Center
Contact Info:
646-888-5080
646-888-6898
Shari Goldfarb, MD

City: Uniondale RECRUITING
Facility: Memorial Sloan Kettering Nassau
Contact Info:
646-888-5080

This Study is Open To:

For Premenopausal Women with Breast Cancer

  • Premenopausal women age 18-44 with 0-III breast cancer, before the start of planned chemotherapy and/or hormonal therapy
  • Have regular menstrual cycles

For High-Risk Premenopausal Women with mutation

  • Premenopausal Women ages 25-45 with known mutation
  • No history of breast or ovarian cancer
  • Have regular menstrual cycles
This Study is Not Open To:

Patients will be excluded if they have:  

General

  • Prior known infertility
  • Family history of a with non-surgical menopause < age 40
  • Current pregnancy

Exclusion Criteria: For Premenopausal Women with Breast Cancer

  • Had prior therapy for breast cancer or any other cancer, such as chemotherapy, hormonal therapy or .
  • Had an ovarian resection, unilateral or oophorectomy, hysterectomy or radiation to pelvic region.
  • Plans for risk-reducing oophorectomy within one year of completion of chemotherapy.

Exclusion Criteria: For High-Risk Premenopausal Women with mutation

  • Had prior chemotherapy or for breast cancer or any other cancer
  • Had an ovarian resection, unilateral or oophorectomy, hysterectomy, radiation to pelvic region, or ovarian disease (e.g. polycystic ovarian syndrome).
  • Plans for risk-reducing oophorectomy within one year